Current Atherosclerosis Reports最新文献_第6页

Inhibition of the ANGPTL3/8 Complex for the Prevention and Treatment of Atherosclerotic Cardiovascular Disease. 抑制 ANGPTL3/8 复合物以预防和治疗动脉粥样硬化性心血管疾病。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-20 DOI: 10.1007/s11883-024-01254-y

Dick C Chan, Gerald F Watts

{"title":"Inhibition of the ANGPTL3/8 Complex for the Prevention and Treatment of Atherosclerotic Cardiovascular Disease.","authors":"Dick C Chan, Gerald F Watts","doi":"10.1007/s11883-024-01254-y","DOIUrl":"10.1007/s11883-024-01254-y","url":null,"abstract":"Purpose of review: Dyslipidemia is a casual risk factor for atherosclerotic cardiovascular disease (ASCVD). There is an unmet need for more effective treatments for patients with dyslipidemias. Angiopoietin-like protein 3 (ANGPTL3) and ANGPTL8 play key roles in triglyceride trafficking and energy balance in humans. We review the functional role of these ANGPTL proteins in the regulation of lipoprotein metabolism, and recent clinical trials targeting ANGPTL3 and ANGPTL3/8 with monoclonal antibody and/or nucleic acid therapies, including antisense oligonucleotides and small interfering RNA.Recent findings: Cumulative evidence supports the roles of ANGPTL3 and ANGPTL8 in lipid metabolism through inhibition of lipoprotein lipase and endothelial lipase activity. ANGPTL3 and ANGPTL3/8 inhibitors are effective in lowering plasma triglycerides and low-density lipoprotein (LDL)-cholesterol, with the possible advantage of raising high-density lipoprotein (HDL)-cholesterol with the inhibition of ANGPTL3/8. Therapeutic inhibition of ANGPTL3 and ANGPTL3/8 can lower plasma triglyceride and LDL-cholesterol levels possibly by lowering production and upregulating catabolism of triglyceride-rich lipoprotein and LDL particles. However, the effect of these novel agents on HDL metabolism remains unclear. The cardiovascular benefits of ANGPTL3 and ABGPTL3/8 inhibitors may also include improvement in vascular inflammation, but this requires further investigation.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"6"},"PeriodicalIF":5.7,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statin-Associated Muscle Symptoms: Identification and Recommendations for Management. 他汀类药物相关肌肉症状：识别与管理建议》。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-18 DOI: 10.1007/s11883-024-01246-y

Kevin C Maki, Carol F Kirkpatrick, Mary Katherine Cheeley, Terry A Jacobson

{"title":"Statin-Associated Muscle Symptoms: Identification and Recommendations for Management.","authors":"Kevin C Maki, Carol F Kirkpatrick, Mary Katherine Cheeley, Terry A Jacobson","doi":"10.1007/s11883-024-01246-y","DOIUrl":"10.1007/s11883-024-01246-y","url":null,"abstract":"Purpose of review: Statins are first-line pharmacotherapy for the treatment of elevated low-density lipoprotein cholesterol and are generally well-tolerated. However, some patients may experience statin-associated muscle symptoms (SAMS). This paper reviews recommendations for identification and management of patients with SAMS.Recent findings: The National Lipid Association and other professional societies have issued guidance to assist clinicians in identifying and managing patients with partial or complete statin intolerance. The most common reason for intolerance is SAMS. This review discusses strategies to achieve therapeutic objectives for atherogenic lipoprotein management in patients with SAMS. Many patients who experience SAMS can tolerate some degree of statin therapy and non-statin medications are available as adjunctive or alternative treatments. With a thorough clinician-patient discussion and shared decision-making, a treatment plan can be identified to achieve therapeutic objectives and reduce the risk of atherosclerotic cardiovascular disease.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"5"},"PeriodicalIF":5.7,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erosion of the Atheroma: Wicked T Cells at the Culprit Site. 动脉粥样斑块的侵蚀：罪魁祸首的邪恶 T 细胞

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-16 DOI: 10.1007/s11883-024-01247-x

Shiying Lin, Yinda Yu, Leif Å Söderström, Anton Gisterå

引用次数: 0

The Emerging Potential of Apolipoprotein C-III Inhibition for ASCVD Prevention: A State-of-the-Art Review. 载脂蛋白 C-III 抑制剂在预防 ASCVD 方面的新潜力：最新研究综述

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-14 DOI: 10.1007/s11883-024-01258-8

Samuel D Maidman, Robert A Hegele, Robert S Rosenson

{"title":"The Emerging Potential of Apolipoprotein C-III Inhibition for ASCVD Prevention: A State-of-the-Art Review.","authors":"Samuel D Maidman, Robert A Hegele, Robert S Rosenson","doi":"10.1007/s11883-024-01258-8","DOIUrl":"10.1007/s11883-024-01258-8","url":null,"abstract":"Purpose of review: Multiple agents are being developed that inhibit apolipoprotein (apo) C-III. This state-of-the-art review examines their potential for atherosclerotic cardiovascular disease (ASCVD) risk reduction.Recent findings: Apo C-III, an apolipoprotein on the surface of triglyceride-rich lipoproteins (TRLs), impairs clearance of TRLs through both lipoprotein lipase dependent and independent pathways, thereby resulting in increased concentrations of triglycerides. Apo C-III has also been shown to have pro-atherogenic effects when bound to high-density lipoprotein (HDL) particles. Classical and genetic epidemiology studies provide support for the concept that apo C-III is associated with an increased risk of ASCVD events. Drug efficacy of agents that silence APOC3 mRNA has been studied in populations with varying hypertriglyceridemia severity, including those with familial chylomicronemia syndrome, multifactorial chylomicronemia syndrome/severe hypertriglyceridemia, and mixed hyperlipidemia. Randomized controlled trials have reported significant reductions in TG and non-HDL cholesterol levels among these patients treated with APOC3 inhibitors. Upcoming clinical outcomes trials seek to establish a role for APOC3 inhibitors to reduce risk of ASCVD.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"3"},"PeriodicalIF":5.7,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence. 他汀类药物会影响认知健康吗？对证据的叙述性回顾和批判性分析。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-09 DOI: 10.1007/s11883-024-01255-x

Richard Kazibwe, Rishi Rikhi, Saeid Mirzai, Nicklaus P Ashburn, Christopher L Schaich, Michael Shapiro

{"title":"Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence.","authors":"Richard Kazibwe, Rishi Rikhi, Saeid Mirzai, Nicklaus P Ashburn, Christopher L Schaich, Michael Shapiro","doi":"10.1007/s11883-024-01255-x","DOIUrl":"10.1007/s11883-024-01255-x","url":null,"abstract":"Purpose of review: Statins are the first-line treatment for hypercholesterolemia and play a key role in the prevention of cardiovascular disease (CVD). Current studies report mixed effects of statins on cognitive health, including harmful, neutral, and protective outcomes. However, these ongoing controversies about the potential cognitive adverse effects of statins may compromise their use in CVD prevention. Several factors may influence how statins affect cognition, including the unique cholesterol homeostasis in the brain, the limited permeability of the blood-brain barrier to lipoproteins, and the varying lipophilicity of different statins. This review examines the evidence linking statins to cognitive function and considers the effect of different dosages and treatment durations.Recent findings: Earlier studies suggested cognitive disturbances with statins, but recent evidence does not strongly support a link between statins and cognitive impairment. In fact, observational studies suggest potential neuroprotective benefits, though biases like selection bias, confounding and reverse causation limit definitive conclusions. Two large randomized controlled trials, STAREE and PREVENTABLE, are underway, and their results are expected to address some of these gaps in the literature. Due to insufficient evidence in the current literature, well-designed randomized controlled trials are needed for a better understanding of statins' effects on cognition. More data is needed regarding statin type, dose intensity, and treatment duration, which may affect cognitive outcomes. Future studies are also needed to examine how statins may affect cognition in specific high-risk groups, such as individuals with mild cognitive impairment, diabetes, cardiovascular disease, or chronic kidney disease.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"2"},"PeriodicalIF":5.7,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Iron in Atherosclerosis and its Association with Related Diseases. 铁在动脉粥样硬化中的作用及其与相关疾病的联系。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-09 DOI: 10.1007/s11883-024-01251-1

Yingbo Gao, Boda Wang, Mengrui Hu, Yuhan Ma, Bin Zheng

{"title":"The Role of Iron in Atherosclerosis and its Association with Related Diseases.","authors":"Yingbo Gao, Boda Wang, Mengrui Hu, Yuhan Ma, Bin Zheng","doi":"10.1007/s11883-024-01251-1","DOIUrl":"https://doi.org/10.1007/s11883-024-01251-1","url":null,"abstract":"Purpose of review: This review aims to elucidate the multifaceted role of iron in the pathogenesis of atherosclerosis. The primary objective is to summarize recent advances in understanding how iron contributes to atherosclerosis through various cellular mechanisms. Additionally, the review explores the therapeutic implications of targeting iron metabolism in the prevention and treatment of cardiovascular diseases.Recent findings: A growing body of literature suggests that excess iron accelerates the progression of atherosclerosis, with the deleterious form of iron, non-transferrin-bound iron (NTBI), particularly exacerbating this process. Furthermore, iron overload has been demonstrated to play a pivotal role in endothelial cells, vascular smooth muscle cells, and macrophages, contributing to plaque instability and disease progression by promoting lipid peroxidation, oxidative stress, inflammatory responses, and ferroptosis. Iron plays a complex role in atherosclerosis, influencing multiple cellular processes and promoting disease progression. By promoting oxidative stress, inflammation, and ferroptosis, iron exacerbates endothelial dysfunction, smooth muscle cell calcification, and the formation of macrophage-derived foam cells. Targeted therapies focusing on iron metabolism have proven effective in treating atherosclerosis and other cardiovascular diseases.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"1"},"PeriodicalIF":5.7,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where? 对患有血脂异常的青少年进行营养干预：谁、做什么、何时、何地？

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-01 Epub Date: 2024-10-23 DOI: 10.1007/s11883-024-01236-0

Maya Rashad, Lauren Williams, Don P Wilson

{"title":"Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?","authors":"Maya Rashad, Lauren Williams, Don P Wilson","doi":"10.1007/s11883-024-01236-0","DOIUrl":"10.1007/s11883-024-01236-0","url":null,"abstract":"Purposeof review: A heart-healthy lifestyle adopted during childhood and sustained throughout life can reduce cardiovascular disease risk in youth with dyslipidemia. In this review, we discuss nutrition recommendations for youth (< 18 years-of-age) with dyslipidemia, compare recommendations for youth versus those for adults, review published data regarding nutrition management in the pediatric population, and discuss strategies for successful implementation in a clinical setting.Recent findings: Recent publications highlight the characteristics of genetic and acquired hypertriglyceridemia disorders, dietary adjuncts used for lipid-lowering, and the effectiveness of a multi-disciplinary team approach. Nutrition interventions remain a cornerstone of lipid management and cardiovascular disease risk reduction in youth with dyslipidemia. Nutrition counseling should include age and developmentally appropriate education while also addressing barriers to implementing a heart-healthy lifestyle. A registered dietitian nutritionist plays an important role within a multidisciplinary clinic setting by providing dietary recommendations to address the needs of youth with dyslipidemia.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"26 11","pages":"609-615"},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Health Data Sciences and Cardiovascular Disease in Africa: Needs and the Way Forward. 非洲的健康数据科学与心血管疾病：需求与未来之路》。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-01 Epub Date: 2024-09-06 DOI: 10.1007/s11883-024-01235-1

Maha Inam, Sana Sheikh, Adeel Khoja, Amina Abubakar, Reena Shah, Zainab Samad, Anthony Ngugi, Farhana Alarakhiya, Akbar Waljee, Salim S Virani

{"title":"Health Data Sciences and Cardiovascular Disease in Africa: Needs and the Way Forward.","authors":"Maha Inam, Sana Sheikh, Adeel Khoja, Amina Abubakar, Reena Shah, Zainab Samad, Anthony Ngugi, Farhana Alarakhiya, Akbar Waljee, Salim S Virani","doi":"10.1007/s11883-024-01235-1","DOIUrl":"10.1007/s11883-024-01235-1","url":null,"abstract":"Purpose of review: The rising burden of cardiovascular disease (CVD) in Africa is of great concern. Health data sciences is a rapidly developing field which has the potential to improve health outcomes, especially in low-middle income countries with burdened healthcare systems. We aim to explore the current CVD landscape in Africa, highlighting the importance of health data sciences in the region and identifying potential opportunities for application and growth by leveraging health data sciences to improve CVD outcomes.Recent findings: While there have been a number of initiatives aimed at developing health data sciences in Africa over the recent decades, the progress and growth are still in their early stages. Its maximum potential can be leveraged through adequate funding, advanced training programs, focused resource allocation, encouraging bidirectional international partnerships, instituting best ethical practices, and prioritizing data science health research in the region. The findings of this review explore the current landscape of CVD and highlight the potential benefits and utility of health data sciences to address CVD challenges in Africa. By understanding and overcoming the barriers associated with health data sciences training, research, and application in the region, focused initiatives can be developed to promote research and development. These efforts will allow policymakers to form informed, evidence-based frameworks for the prevention and management of CVDs, and ultimately result in improved CVD outcomes in the region.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"659-671"},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Should We Use Aspirin or P2Y₁₂ Inhibitor Monotherapy in Stable Ischemic Heart Disease? 稳定型缺血性心脏病应该使用阿司匹林还是 P2Y12 抑制剂单药治疗？

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-01 Epub Date: 2024-09-07 DOI: 10.1007/s11883-024-01234-2

Rishi Chandiramani, Adhya Mehta, Roger S Blumenthal, Marlene S Williams

{"title":"Should We Use Aspirin or P2Y12 Inhibitor Monotherapy in Stable Ischemic Heart Disease?","authors":"Rishi Chandiramani, Adhya Mehta, Roger S Blumenthal, Marlene S Williams","doi":"10.1007/s11883-024-01234-2","DOIUrl":"10.1007/s11883-024-01234-2","url":null,"abstract":"Purpose of review: To summarize the recent evidence and guideline recommendations on aspirin or P2Y12 inhibitor monotherapy in patients with stable ischemic heart disease and provide insights into future directions on this topic, which involves transition to a personalized assessment of bleeding and thrombotic risks.Recent findings: It has been questioned whether the evidence for aspirin as the foundational component of secondary prevention in patients with coronary artery disease aligns with contemporary pharmaco-invasive strategies. The recent HOST-EXAM study randomized patients who had received dual antiplatelet therapy for 6 to 18 months without ischemic or major bleeding events to either clopidogrel or aspirin for a further 24 months, and demonstrated that the patients in the clopidogrel arm had significantly lower rates of both thrombotic and bleeding complications compared to those in the aspirin arm. The patient-level PANTHER meta-analysis showed that in patients with established coronary artery disease, P2Y12 inhibitor monotherapy was associated with lower rates of myocardial infarction, stent thrombosis as well as gastrointestinal bleeding and hemorrhagic stroke compared to aspirin monotherapy, albeit with similar rates of all-cause mortality, cardiovascular mortality and major bleeding. Long-term low-dose aspirin is recommended for secondary prevention in patients with stable ischemic heart disease, with clopidogrel monotherapy being acknowledged as a feasible alternative. Dual antiplatelet therapy for six months after percutaneous coronary intervention remains the standard recommendation for patients with stable ischemic heart disease. However, the duration of dual antiplatelet therapy may be shortened and followed by P2Y12 inhibitor monotherapy or prolonged based on individualized evaluation of the patient's risk profile.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"649-658"},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice? 临床实践中，青少年心血管健康管理的家族史是否仍有意义？

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-01 Epub Date: 2024-08-27 DOI: 10.1007/s11883-024-01232-4

Daphney Kernizan, Sean Connolly, Dima Turpin, Abbas Zaidi, Carissa M Baker-Smith

{"title":"Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice?","authors":"Daphney Kernizan, Sean Connolly, Dima Turpin, Abbas Zaidi, Carissa M Baker-Smith","doi":"10.1007/s11883-024-01232-4","DOIUrl":"10.1007/s11883-024-01232-4","url":null,"abstract":"Purpose of review: Family history of premature cardiovascular disease is a strong predictor of individual cardiovascular risk. However, family history is not always available and not always reliable. Roughly 80% of health outcomes are influenced not by genetic risk but by societal factors, including adverse health behaviors and environment. Furthermore, in the present age of genetic testing, laboratory evaluations, and imaging, a key question remains: What is the contemporary relevance of family history screening in the management of cardiovascular disease in youth?Recent findings: Knowledge of an individual's family history can help clinicians identify not only inherited risk but also familial clustering of unhealthy behaviors and environmental adversity contributing to enhanced cardiovascular disease risk in youth. For those at greatest risk, prevention strategies can be applied sooner and more conservatively. Integrating family history into clinical practice is crucial for cardiovascular risk assessment and for optimizing outcomes, but, in some cases, is more reflective of social factors.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"629-637"},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0